載入...
Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
Sequential chemotherapy may improve treatment efficacy avoiding the additive toxicity associated with concomitant polichemotherapy in hormone-refractory prostate cancer (HRPC). Forty patients received docetaxel 30 mg m(−2) intravenous (i.v.), weekly, plus estramustine 280 mg twice daily for 12 weeks...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group
2007
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2360275/ https://ncbi.nlm.nih.gov/pubmed/18026196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604090 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|